Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Nat, Lenzo"'
Autor:
Mohammed Al-Zubaidi, Elizabeth Liow, Dickon Hayne, Andrew D Redfern, Tom Ferguson, Steve McCombie, Pravin Viswambaram, Nat Lenzo, Richard Gauci
Publikováno v:
BMJ Open, Vol 12, Iss 4 (2022)
Introduction Bladder cancer is a lethal disease with a rising incidence on a background of limited conventional imaging modalities for staging (either CT of the chest-abdomen-pelvis or 18F-fluorodeoxyglucose positron emitting tomography (FDG-PET/CT))
Externí odkaz:
https://doaj.org/article/08588462c0a448678e8048e2b36bf858
Publikováno v:
6th International Conference on Radiopharmaceutical Therapy (ICRT 2021) Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8f556d9c1e166e655b9a44bd25ab1a1
https://doi.org/10.1055/s-0042-1749238
https://doi.org/10.1055/s-0042-1749238
Publikováno v:
Journal of Clinical Oncology. 41:318-318
318 Background: Prostate cancer (PC) is the second most frequent malignancy in men worldwide. 68Ga-PSMA-11 is one of the most widely used radiotracers for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b5bb60577e4e7f44239a6112ca2094a
https://doi.org/10.1200/jco.2023.41.6_suppl.318
https://doi.org/10.1200/jco.2023.41.6_suppl.318
Publikováno v:
Clinical Kidney Journal
Background Radioligand therapy (RLT) with 177lutetium (Lu)-labelled prostate-specific membrane antigen (PSMA) ligands has been increasingly used in recent years for therapy of metastatic castrate-resistant prostate cancer (mCRPC). Studies have reveal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30ba5d69a6d9beb028c1bdbde743068f
http://europepmc.org/articles/PMC7769531
http://europepmc.org/articles/PMC7769531
Autor:
Jingjing Zhang, Kalevi Kairemo, Finn Edler von Eyben, Nat Lenzo, Danielle Meyrick, Harshad R. Kulkarni, Karin Nipsch, Timo Joensuu, Irene Virgolini, Aviral Singh, Cigdem Soydal, Richard P. Baum
Publikováno v:
Oncotarget
177Lu-PSMA radioligand therapy (LuPRLT) is mainly used for patients with metastatic castration-resistant prostate cancer who are resistant to established drugs. This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bb68b337659e6128ab7e7e17a6fda78
https://doi.org/10.18632/oncotarget.26789
https://doi.org/10.18632/oncotarget.26789
Publikováno v:
World Journal of Nuclear Medicine, Vol 18, Iss 3, Pp 232-237 (2019)
World Journal of Nuclear Medicine
World Journal of Nuclear Medicine
The aim of this study was to evaluate if prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has a higher detection rate compared to standard contrast CT imaging for patients with a rising prostate-spec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a111a26b17aea5ff5c8a34dc32d7b6d
http://www.wjnm.org/article.asp?issn=1450-1147
http://www.wjnm.org/article.asp?issn=1450-1147
Autor:
Sharon Yeo, Murali Kesavan, Marat O. Gallyamov, J. Harvey Turner, Nat Lenzo, Danielle Meyrick, Giuseppe Cardaci
Publikováno v:
Diagnostics, Vol 11, Iss 515, p 515 (2021)
Diagnostics
Diagnostics
Background: Metastatic castration-resistant prostate cancer (mCRPC) remains a significant contributor to the global cancer burden. lutetium-177-prostate-specific membrane antigen radioligand therapy (177Lu-PSMA RLT) is an effective salvage treatment.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4812d2fb20f6989ed5353eadc9f2b41
https://www.mdpi.com/2075-4418/11/3/515
https://www.mdpi.com/2075-4418/11/3/515
Publikováno v:
Targeted oncology. 16(3)
Lutetium-177 prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy is emerging as a promising treatment for metastatic castration-resistant prostate cancer refractory to established therapies. While there is an increasing body of surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9248f1c00904de6cd8f51e1b144b3a1a
https://pubmed.ncbi.nlm.nih.gov/33687624
https://pubmed.ncbi.nlm.nih.gov/33687624
Autor:
Dickon Hayne, Richard Gauci, Mohammed Al-Zubaidi, Pravin Viswambaram, Steve P McCombie, Elizabeth Chien Hern Liow, Nat Lenzo, Thomas Ferguson, Paola Antonini, Danielle Meyrick, Colin Hayward, Andrew David Redfern
Publikováno v:
Journal of Clinical Oncology. 40:TPS4609-TPS4609
TPS4609 Background: Bladder cancer is a lethal disease with a rising incidence. The current standard imaging modalities for staging are either CT of the chest, abdomen and pelvis or FDG PET/CT. However, there are issues with using these modalities fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::137dca2e450959abebd484ce14fad245
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4609
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4609
Publikováno v:
Nuclear Medicine Communications. 38:956-963
This retrospective study aimed to evaluate the role of Ga-PSMA-IT PET/CT in the primary staging of newly diagnosed prostate cancer (PCa), with a focus on the detection of metastatic nodal disease. Correlation of the rate of detection of metastatic di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::506ec494da732f3e797d663105b25d5b
https://doi.org/10.1097/mnm.0000000000000738
https://doi.org/10.1097/mnm.0000000000000738